FIELD: medicine.
SUBSTANCE: combined drug for the treatment of cancer or improvement of the condition in cancer is proposed, which contains soluble protein LAG-3 or protein LAG-3 derivative, which contains recombinant soluble human fused protein LAG-3Ig IMP321, and a path inhibitor of programmed cell death 1 (hereinafter – PD-1) protein, containing an anti-PD-1 antibody or an anti-PD-L1 antibody. The use of a combined drug for the treatment of cancer or improvement of the condition in cancer is proposed.
EFFECT: proposed group of inventions provides for synergetic activation of T-cells for the prevention, treatment or improvement of cancer.
14 cl, 19 dwg, 27 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| MEDICINAL PRODUCT | 2017 |
|
RU2759728C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT | 2019 |
|
RU2794261C2 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
